

# Xiaoying Shen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6408959/publications.pdf>

Version: 2024-02-01

86  
papers

7,314  
citations

94433

37  
h-index

60623

81  
g-index

90  
all docs

90  
docs citations

90  
times ranked

7207  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. <i>Journal of Infectious Diseases</i> , 2022, 225, 856-861.	4.0	22
2	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	12.4	93
3	Towards a population-based threshold of protection for COVID-19 vaccines. <i>Vaccine</i> , 2022, 40, 306-315.	3.8	107
4	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	27.0	338
5	Boosting immunity to Omicron. <i>Nature Medicine</i> , 2022, 28, 445-446.	30.7	29
6	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	27.8	117
7	Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies. <i>Cell Reports</i> , 2022, 38, 110436.	6.4	6
8	Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals. <i>Journal of Infectious Diseases</i> , 2022, 226, 1407-1411.	4.0	6
9	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , 2021, 594, 253-258.	27.8	253
10	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	6.0	46
11	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. <i>Cell Host and Microbe</i> , 2021, 29, 529-539.e3.	11.0	324
12	Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. <i>New England Journal of Medicine</i> , 2021, 384, 2352-2354.	27.0	202
13	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009624.	4.7	2
14	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	11.9	53
15	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020, 5, 107.	6.0	11
16	RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines. <i>Scientific Reports</i> , 2020, 10, 14056.	3.3	4
17	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. <i>PLoS Pathogens</i> , 2020, 16, e1008764.	4.7	37
18	Impact of T <sub>H</sub> 1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	30

#	ARTICLE	IF	CITATIONS
19	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	6.4	43
20	Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. <i>PLoS Pathogens</i> , 2020, 16, e1008377.	4.7	14
21	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	3.3	17
22	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020, 30, 1553-1569.e6.	6.4	21
23	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	8
24	A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities. <i>Journal of Virology</i> , 2020, 94, .	3.4	4
25	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	12.8	35
26	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	3.4	26
27	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	46
28	Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. <i>Journal of Virology</i> , 2019, 93, .	3.4	15
29	Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. <i>Journal of Virology</i> , 2019, 93, .	3.4	20
30	HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. <i>Nature Communications</i> , 2019, 10, 798.	12.8	61
31	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. <i>PLoS Pathogens</i> , 2019, 15, e1008121.	4.7	19
32	Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2019, 93, .	3.4	18
33	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. <i>Journal of Clinical Investigation</i> , 2019, 129, 1314-1328.	8.2	28
34	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	8.2	95
35	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	3.4	46
36	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	4.0	32

#	ARTICLE	IF	CITATIONS
37	A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	30
38	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	3.4	45
39	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	4.4	26
40	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. <i>PLoS ONE</i> , 2018, 13, e0194266.	2.5	14
41	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2018, 24, 847-856.	30.7	65
42	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018, 14, e1006986.	4.7	28
43	Control of Heterologous Simian Immunodeficiency Virus SIV <sub>smE660</sub> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	39
44	Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. <i>Retrovirology</i> , 2018, 15, 24.	2.0	0
45	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	39
46	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. <i>Journal of Immunology</i> , 2017, 198, 1047-1055.	0.8	7
47	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. <i>Journal of Virology</i> , 2017, 91, .	3.4	29
48	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017, 91, .	3.4	5
49	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	12.8	137
50	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	3.4	23
51	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. <i>Vaccine Journal</i> , 2017, 24, .	3.1	28
52	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	6.4	97
53	Computational analysis of antibody dynamics identifies recent HIV-1 infection. <i>JCI Insight</i> , 2017, 2, .	5.0	11
54	Changes in Circulating B Cell Subsets Associated with Aging and Acute SIV Infection in Rhesus Macaques. <i>PLoS ONE</i> , 2017, 12, e0170154.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. <i>PLoS ONE</i> , 2016, 11, e0152038.	2.5	37
56	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	8.2	41
57	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <i>Journal of Immunology</i> , 2016, 197, 2726-2737.	0.8	34
58	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. <i>Journal of Virology</i> , 2016, 90, 8644-8660.	3.4	13
59	Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. <i>Journal of Virology</i> , 2016, 90, 8842-8854.	3.4	34
60	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	30.7	197
61	Envelope residue 375 substitutions in simian human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	7.1	170
62	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016, 90, 4951-4965.	3.4	23
63	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	4.7	145
64	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
65	CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection. <i>Journal of Virology</i> , 2015, 89, 4690-4695.	3.4	31
66	Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses. <i>Journal of Infectious Diseases</i> , 2015, 211, 508-517.	4.0	57
67	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	12.4	47
68	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8643-8650.	3.4	42
69	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8525-8539.	3.4	35
70	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	11.0	66
71	Aggregate complexes of HIV-1 induced by multimeric antibodies. <i>Retrovirology</i> , 2014, 11, 78.	2.0	26
72	Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity. <i>Journal of Virology</i> , 2014, 88, 5165-5170.	3.4	41

#	ARTICLE	IF	CITATIONS
73	DNA and Protein Co-immunization Improves the Magnitude, Longevity, and Mucosal Dissemination of Immune Responses. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A63-A64.	1.1	0
74	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDS VAXA® B/E in RV144 Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A36-A36.	1.1	1
75	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 4843-4856.	8.2	25
76	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9019-9024.	7.1	371
77	DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2975-2980.	7.1	71
78	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDS VAX HIV-1 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e53629.	2.5	165
79	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e75665.	2.5	214
80	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1444-1457.	1.1	191
81	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	27.0	1,699
82	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 11502-11519.	3.4	168
83	Alterations of the B-Cell Response by HIV-1 Replication. <i>Current HIV/AIDS Reports</i> , 2011, 8, 23-30.	3.1	32
84	HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies. <i>Journal of Virology</i> , 2011, 85, 9555-9567.	3.4	86
85	Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5972-5977.	7.1	57
86	In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth. <i>Journal of Virology</i> , 2009, 83, 3617-3625.	3.4	94